Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapagliflozin - AstraZeneca

Next Previous
Drug Profile

Dapagliflozin - AstraZeneca

Alternative Names: Andatang; AZ-dapagliflozin; BMS-512148; BMS-dapagliflozin; BMS/AZ-Dapagliflozin; DAPA; Dapagliflozin-AstraZeneca; Dapagliflozin-propanediol; Farxiga; Forxiga; Oxra

Latest Information Update: 05 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; AstraZeneca KK; Bayer; Bristol-Myers Squibb; Novo Nordisk Foundation; Ono Pharmaceutical; University Medical Center Groningen; Uppsala University
  • Class Anti-ischaemics; Antihyperglycaemics; Antivirals; Benzhydryl compounds; Cardiovascular therapies; Chlorobenzenes; Glucosides; Heart failure therapies; Hepatoprotectants; Obesity therapies; Pyrans; Small molecules; Urologics
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Chronic heart failure; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Phase III COVID 2019 infections; Heart failure; Myocardial infarction
  • Phase II Kidney disorders; Liver cirrhosis; Obesity; Prediabetic state

Most Recent Events

  • 05 Sep 2025 AstraZeneca completes a phase I DAPAG-02-23 bioequivalence study (In volunteers) in Romania (CTIS2023-506408-18-00)
  • 09 May 2025 AstraZeneca completes the phase-II MIRO-CKD trial for Renal failure (Treatment-experienced) in USA, Austria, Brazil, Bulgaria, Canada, China, Italy, Japan, Malaysia, Poland, Spain, Taiwan, Turkey, United Kingdom and Vietnam (PO), (NCT06350123)
  • 09 Sep 2024 Pharmacodynamics, efficacy and adverse events data from phase III T2NOW trial for Type 2 diabetes mellitus presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top